Efficacy and safety of first-ever Dengue vaccine candidate in Phase 3

被引：0
|
作者：
Riedmann, Eva M.
机构：
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2014年 / 10卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：2139 / 2139
页数：1
相关论文
共 50 条
  • [21] Determinants of Fatigue after First-Ever lschemic Stroke NE during Acute Phase
    Wang, Shan-Shan
    Wang, Jia-Ji
    Wang, Pei-Xi
    Chen, Ruoling
    PLOS ONE, 2014, 9 (10):
  • [22] Acute phase factors associated with the course of depression during the first 18 months after first-ever stroke
    Eriksen, Siren
    Gay, Caryl L.
    Lerdal, Anners
    DISABILITY AND REHABILITATION, 2016, 38 (01) : 30 - 35
  • [23] Prediction of 3-month mortality after first-ever acute ischemic stroke
    Chang, KC
    Tseng, MC
    Tan, TY
    Liou, CW
    STROKE, 2003, 34 (01) : 320 - 321
  • [24] Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials
    Juraska, Michal
    Magaret, Craig A.
    Shao, Jason
    Carpp, Lindsay N.
    Fiore-Gartland, Andrew J.
    Benkeser, David
    Girerd-Chambaz, Yves
    Langevin, Edith
    Frago, Carina
    Guy, Bruno
    Jackson, Nicholas
    Kien Duong Thi Hue
    Simmons, Cameron P.
    Edlefsen, Paul T.
    Gilbert, Peter B.
    Simmons, Cameron P.
    Edlefsen, Paul T.
    Gilbert, Peter B.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (36) : E8378 - E8387
  • [25] Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial
    de Bruyn, Guy
    Gordon, David L.
    Steiner, Theodore
    Tambyah, Paul
    Cosgrove, Catherine
    Martens, Mark
    Bassily, Ehab
    Chan, Eng-Soon
    Patel, Dhaval
    Chen, Josh
    Torre-Cisneros, Julian
    De Magalhaes Francesconi, Carlos Fernando
    Gesser, Richard
    Jeanfreau, Robert
    Launay, Odile
    Laot, Thelma
    Morfin-Otero, Rayo
    Oviedo-Orta, Ernesto
    Park, Yoon Soo
    Piazza, Franco M.
    Rehm, Christine
    Rivas, Enrique
    Self, Steve
    Gurunathan, Sanjay
    LANCET INFECTIOUS DISEASES, 2021, 21 (02): : 252 - 262
  • [26] Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
    Turner, Mark
    Papadimitriou, Athanasia
    Winkle, Peter
    Segall, Nathan
    Levin, Michael
    Doust, Matthew
    Johnson, Casey
    Lucksinger, Gregg
    Fierro, Carlos
    Pickrell, Paul
    Raanan, Marsha
    Tricou, Vianney
    Borkowski, Astrid
    Wallace, Derek
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (10) : 2456 - 2464
  • [27] Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study
    Sirivichayakul, Chukiat
    Barranco-Santana, Elizabeth A.
    Esquilin-Rivera, Ines
    Oh, Helen M. L.
    Raanan, Marsha
    Sariol, Carlos A.
    Shek, Lynette P.
    Simasathien, Sriluck
    Smith, Mary Kathryn
    Dario Velez, Ivan
    Wallace, Derek
    Gordon, Gilad S.
    Stinchcomb, Dan T.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (10): : 1562 - 1572
  • [28] Safety and efficacy of a Mycoplasma gallisepticum oppD knockout mutant as a vaccine candidate
    Tseng, Chi-Wen
    Chiu, Chien-Ju
    Kanci, Anna
    Noormohammadi, Amir H.
    Browning, Glenn F.
    Markham, Philip F.
    VACCINE, 2017, 35 (45) : 6248 - 6253
  • [29] NIH dengue vaccine leaps into phase 3 studies
    Perkel, Jeffrey M.
    NATURE BIOTECHNOLOGY, 2016, 34 (05) : 449 - 449
  • [30] NIH dengue vaccine leaps into phase 3 studies
    Perkel J.M.
    Nature Biotechnology, 2016, 34 (5) : 449 - 449
12345